Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVI Global Trust Regulatory News (AGT)

Share Price Information for AVI Global Trust (AGT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 234.50
Bid: 234.50
Ask: 236.00
Change: -1.00 (-0.42%)
Spread: 1.50 (0.64%)
Open: 234.50
High: 235.00
Low: 234.50
Prev. Close: 235.50
AGT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monthly Update

16 Aug 2022 13:55

RNS Number : 2135W
AVI Global Trust PLC
16 August 2022
 

 

AVI GLOBAL TRUST PLC

 

Monthly Update

 

AVI Global Trust plc (the "Company") presents its Update, reporting performance figures for the month ended 31 July 2022.

 

This Monthly Newsletter is available on the Company's website at:

https://www.assetvalueinvestors.com/agt/content/uploads/2022/08/AGT-July-2022.pdf

 

 

Performance Total Return

 

This investment management report relates to performance figures to 31 July 2022.

 

Month

Fiscal Yr*

to date

Calendar Yr

to date

AGT NAV1

5.2%

-2.4%

-8.4%

MSCI ACWI Ex US2

3.2%

-4.8%

-6.1%

MSCI ACWI1

6.8%

0.9%

-5.0%

 

1

Source: Morningstar. All NAV figures are cum-fair values.

2

From 1st October 2013 the lead benchmark was changed to the MSCI ACWI ex US (£) Index. The investment management fee was changed to 0.7% of net assets and the performance related fee eliminated.

 

* All return figures in GBP. AVI Global Trust financial year commences on the 1st October. All figures published before the fiscal results announcement are AVI estimates and subject to change.

 

Manager's Comment

 

AVI Global Trust (AGT)'s NAV increased by +5.2% in July.

 

Performance was broad-based as global markets rallied. The extent to which this is a relief rally or something more meaningful is yet to be seen. There are lots of reasons to think it is the former, but we remain open-minded.

 

Six companies - KKR, EXOR, Pershing Square Holdings, Oakley Capital Investments, Christian Dior and Apollo Global Management - all contributed between 55bps and 103bps. IAC, FEMSA and Third Point Investors were notable detractors.

 

Over the course of the month the portfolio weighted average discount narrowed slightly, from 34.1% to 33.2%.

 

Christian Dior ("CDI") was a meaningful contributor to returns during a period in which LVMH (100% of CDI NAV) reported a strong set of results for the first half of 2022. The shares and NAV returned +17% and +16% over the month, with a slight narrowing of the discount to 15%.

Even with a headwind of continued restrictions in China, the business is performing at a very high level. Sales were up +21% organically and operating profits increased by more than one third to €10.2bn - some +6% better than consensus analyst expectations. The all-important Fashion & Leather division - home to Louis Vuitton and Christian Dior - achieved a 41% operating margin, with profits well more than double their 2019 level. Management believe that a >40% margin is the "new normal" - with Christian Dior an increasingly integral part of this.

We have noted in the past that we expect "mega-brands" to outperform given the considerable scale advantages in luxury. Recent results seem to re-affirm this. We also note the recent proposal for Tods, the Italian-listed luxury shoemaker, to be taken private by the founder. Tods has more than tripled sales over the last twenty plus years as a public company, but profits have barely budged - highlighting how hard it is for small luxury goods companies to compete. Our expectation is that winners will continue to win, and that LVMH will continue to drive attractive returns.

Shares in LVMH are down -6% year to date, yet operational performance and the reporting of three sets of strong results have forced consensus expectations higher, with EBIT estimates for this year and the next two years increasing +16% / +14% / +18% year to date. The multiple has thereby compressed, with LVMH trading at an EV/EBIT multiple of 17.1x, back below its long-term average.

At 15% CDI's discount is slightly wider than where it started the year. Our expectation is that over time the Arnault family will collapse the structure, having taken numerous steps to simplify their group holding companies in recent years. As such we view the fair discount as zero. In the meantime, time is our friend as we expect the NAV to keep compounding at an attractive rate.

FEMSA:

FEMSA was a detractor as the shares declined -8% during a month in which the company launched a tender offer to acquire Swiss convenience store and food service operator Valora, for $1.2bn in cash (3% of NAV). The market reacted negatively - with the shares down -12% in the three days following the announcement.

We share the markets' concerns and view the proposed acquisition as a frustrating unforced error, which complicates the equity story and as such the probable discount / stub multiple at which FEMSA will trade. From a returns perspective it also seems highly dubious that this is a better use of capital than buying back shares.

 

With that said, investing is an expectations game - not an academic exercise of absolutist judgements - and expectations are currently very low. In our view, the above concerns are more than reflected in the share price, with the stub trading under 6x forward EBITDA, a new low and a record (~60%) discount to Walmex.

 

Operational performance - which in the long-run should translate to shareholder returns - remains strong. Indeed, results at the end of July showed the Proximity Division (Oxxo) to be growing sales +18% organically, with +34% growth in operating profit as margins reached a new high for the second quarter (10.2%). Coupled with the upcoming completion of the strategic review, and the possibility of strategic or equity partnerships for Spin, their digital wallet, there are a number of potential catalysts to reset the narrative and drive the shares higher.

 

We modestly added to the position in July.

 

Trading activity

 

Having reduced gearing during the second half of 2021 we have considerable firepower to invest in new and existing ideas. So far this year we have been cautious and patient in our approach, although in July we started to build a number of smaller positions.

 

Contributors / Detractors (in GBP)

 

Largest Contributors

1- month contribution

bps

% of NAV

KKR

103

6.0

EXOR

77

6.8

Pershing Square Holdings

75

8.5

Oakley Capital Investments

73

6.6

Christian Dior

60

4.7

 

Largest Detractors

1- month contribution

bps

% of NAV

IAC/InterActiveCorp

-34

2.9

FEMSA

-30

3.5

Third Point Investors

-27

3.1

Swire Pacific Ltd 'B'

-24

-

Fondul Proprietatea

-14

0.5

 

 

 

Link Company Matters Limited

Corporate Secretary

 

16 August 2022

 

LEI: 213800QUODCLWWRVI968

 

The content of the Company's web-pages and the content of any website or pages which may be accessed through hyperlinks on the Company's web-pages, other than the content of the Newsletter referred to above, is neither incorporated into nor forms part of the above announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DOCLQLFFLVLEBBX
Date   Source Headline
14th Jun 20245:27 pmRNSTransaction in Own Shares
14th Jun 20241:40 pmRNSNet Asset Value(s)
13th Jun 20241:34 pmRNSNet Asset Value(s)
12th Jun 20241:24 pmRNSNet Asset Value(s)
11th Jun 20242:53 pmRNSNet Asset Value(s)
11th Jun 20241:26 pmRNSMonthly Update
10th Jun 202412:29 pmRNSNet Asset Value(s)
7th Jun 20241:02 pmRNSNet Asset Value(s)
6th Jun 20245:18 pmRNSTransaction in Own Shares
6th Jun 202412:05 pmRNSNet Asset Value(s)
5th Jun 20244:39 pmRNSDirector/PDMR Shareholding
5th Jun 202412:47 pmRNSNet Asset Value(s)
5th Jun 20247:00 amRNSHalf-year Report
4th Jun 202412:27 pmRNSNet Asset Value(s)
3rd Jun 20243:59 pmRNSNet Asset Value(s)
3rd Jun 202410:12 amRNSTotal Voting Rights
31st May 20243:47 pmRNSNet Asset Value(s)
30th May 20243:06 pmRNSNet Asset Value(s)
29th May 20245:31 pmRNSTransaction in Own Shares
29th May 20241:15 pmRNSNet Asset Value(s)
28th May 20243:48 pmRNSNet Asset Value(s)
24th May 20243:08 pmRNSNet Asset Value(s)
23rd May 20245:14 pmRNSTransaction in Own Shares
23rd May 20242:32 pmRNSNet Asset Value(s)
22nd May 202412:36 pmRNSNet Asset Value(s)
21st May 20245:45 pmRNSTransaction in Own Shares
21st May 20244:48 pmRNSHolding(s) in Company
21st May 20241:11 pmRNSNet Asset Value(s)
20th May 20241:08 pmRNSNet Asset Value(s)
17th May 202412:50 pmRNSNet Asset Value(s)
16th May 20245:55 pmRNSTransaction in Own Shares
16th May 20242:44 pmRNSHolding(s) in Company
16th May 20241:34 pmRNSNet Asset Value(s)
15th May 20245:43 pmRNSTransaction in Own Shares
15th May 20245:19 pmRNSMonthly Factsheet
15th May 20241:20 pmRNSNet Asset Value(s)
14th May 20241:05 pmRNSNet Asset Value(s)
13th May 20241:00 pmRNSNet Asset Value(s)
10th May 20244:43 pmRNSHolding(s) in Company
10th May 20241:35 pmRNSNet Asset Value(s)
9th May 20245:55 pmRNSTransaction in Own Shares
9th May 202412:46 pmRNSNet Asset Value(s)
8th May 20241:27 pmRNSNet Asset Value(s)
7th May 20241:18 pmRNSNet Asset Value(s)
3rd May 20242:08 pmRNSNet Asset Value(s)
2nd May 20245:43 pmRNSTransaction in Own Shares
2nd May 20241:55 pmRNSNet Asset Value(s)
1st May 20241:39 pmRNSNet Asset Value(s)
1st May 20247:00 amRNSTotal Voting Rights
30th Apr 202412:30 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.